JW Therapeutics Announces Initiation of Clinical Study of Carteyva® in First-line Treatment in Patients with High-Risk Large B-Cell Lymphoma

/PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing...

Related Keywords

China ,Shanghai ,United Kingdom ,Ying Zhao ,A Bristol Myers Squibb ,National Significant New Drug Development Program ,International Prognostic Index ,Intergroup Trial Alliance ,China National Medical Products Administration ,China Association Lymphoma Committee ,Anti Cancer Association Lymphoma Committee ,Chinj Oncol ,Relmacabtagene Autoleucel Injection ,Juno Therapeutics ,Bristol Myers Squibb ,Jw Therapeutics ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Biotechnology ,Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,